Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Ausun Pharmaceutical CoSHSE:603229 83 Interest Coverage is 48.87 as of Mar. 2026, which is 71% above its 10-year median of 28.66. GuruFocus rates SHSE:603229 with a GF Score™ of 83/100 and a GF Value™ of ¥10.22 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 376 Biotechnology companies, Zhejiang Ausun Pharmaceutical Co ranks worse than 71.81% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Zhejiang Ausun Pharmaceutical Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥138.1 Mil. Zhejiang Ausun Pharmaceutical Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-2.8 Mil.
Zhejiang Ausun Pharmaceutical Co's interest coverage for the quarter that ended in Mar. 2026 was 48.87.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Zhejiang Ausun Pharmaceutical Co's Interest Coverage or its related term are showing as below:
SHSE:603229'
s Interest Coverage Range Over the Past 10 Years
Min: 9.94 Med: 28.66 Max: 108.79
Current: 15.32
SHSE:603229's Interest Coverage is ranked worse than 71.81% of 376
companies
in the Biotechnology industry
Industry Median: 104.025
vs SHSE:603229: 15.32
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Zhejiang Ausun Pharmaceutical Co Interest Coverage Related Terms
Zhejiang Ausun Pharmaceutical Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Zhejiang Ausun Pharmaceutical Co Interest Coverage Chart
SHSE:603229 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Zhejiang Ausun Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Ausun Pharmaceutical Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhejiang Ausun Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Zhejiang Ausun Pharmaceutical Co's Interest Coverage falls into.
Zhejiang Ausun Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) has a Interest Coverage of 48.87 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. This is 71% above median its historical median of 28.66. Over the past decade, Zhejiang Ausun Pharmaceutical Co's Interest Coverage has ranged from 9.94 to 108.79. According to the industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #270 out of 376 companies in the Biotechnology industry, placing it in the top 71.8%.
Is Zhejiang Ausun Pharmaceutical Co's Interest Coverage too high?
Zhejiang Ausun Pharmaceutical Co's current Interest Coverage of 48.87 is 71% above median its 10-year median of 28.66. Over the past 10 years, this metric has ranged from a low of 9.94 to a high of 108.79. The Biotechnology industry median Interest Coverage is 104.03. Zhejiang Ausun Pharmaceutical Co's value of 48.87 is 53% below this industry median. Based on the distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #270 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zhejiang Ausun Pharmaceutical Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Ausun Pharmaceutical Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #270 out of 376 companies for Interest Coverage. This places Zhejiang Ausun Pharmaceutical Co in the lower half of its industry. The industry median Interest Coverage is 104.03. Zhejiang Ausun Pharmaceutical Co's value of 48.87 is 53% below this benchmark. Historically, Zhejiang Ausun Pharmaceutical Co's own Interest Coverage has ranged from 9.94 to 108.79 over the past decade. While the company's 10-year median is 28.66 vs. the industry median of 104.03, Zhejiang Ausun Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Ausun Pharmaceutical Co's current Interest Coverage of 48.87 is 53% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Ausun Pharmaceutical Co's current Interest Coverage is 48.87, which is 71% above median its own 10-year median of 28.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Ausun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co (SHSE:603229) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.22, compared to a current price of ¥8.09 — trading 20.8% below its estimated fair value. The current Interest Coverage is 48.87, which is 71% above median its 10-year median of 28.66 and 53% below the Biotechnology industry median of 104.03. Zhejiang Ausun Pharmaceutical Co's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Zhejiang Ausun Pharmaceutical Co (SHSE:603229), the current Interest Coverage is 48.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.09 is trading 20.8% below its estimated GF Value™ of ¥10.22.
GuruFocus considers Zhejiang Ausun Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603229:
Interest Coverage: 48.87 (71% above median its 10-year median of 28.66)
GF Value™: ¥10.22 vs. price of ¥8.09 (20.8% below fair value)
Industry Position: 53% below the Biotechnology median (#270 of 376)
No single metric tells the full story. See the SHSE:603229 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Ausun Pharmaceutical Co Business Description
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
83GF Score
Get the complete analysis for SHSE:603229
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603229 has been successfully added to your 
